2013
DOI: 10.1016/j.phrs.2012.11.009
|View full text |Cite
|
Sign up to set email alerts
|

Onabotulinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
20
0

Year Published

2013
2013
2020
2020

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 28 publications
(22 citation statements)
references
References 28 publications
2
20
0
Order By: Relevance
“…Reduced NGF immunofluorescence in detrusor following bladder wall injection of NGF antisense corroborates with the reported decrease in NGF after intradetrusor injection of botulinum toxin in OAB patients (Giannantoni et al, 2013). Bladder wall injection of NGF antisense is effective at 22 fold lower dose of ODN compared to intravesical instillation (Kashyap et al, 2013), which may prove to be cost effective when ODN is available in limited supply.…”
Section: Discussionsupporting
confidence: 87%
“…Reduced NGF immunofluorescence in detrusor following bladder wall injection of NGF antisense corroborates with the reported decrease in NGF after intradetrusor injection of botulinum toxin in OAB patients (Giannantoni et al, 2013). Bladder wall injection of NGF antisense is effective at 22 fold lower dose of ODN compared to intravesical instillation (Kashyap et al, 2013), which may prove to be cost effective when ODN is available in limited supply.…”
Section: Discussionsupporting
confidence: 87%
“…The TRPV1 receptors were found in the theca-interstitial cells of the follicles, with low expression at P10 that increased at the onset of pu-berty (FVO). These results are consistent with the expression of TRPV1 receptors in many tissues depending on cell type and activity [41,42]. In retina cells and pulmonary arterial smooth muscle cells, TRPV1 receptors promote cell proliferation and migration by MAPK intracellular signal activation [43,44].…”
Section: Discussionsupporting
confidence: 85%
“…Even the least optimistic study still reported that 30% of NDO patients responded to treatment with RTX (Kuo, ). Interestingly, it was recently shown that botulinum toxin A, which is used as a second‐line treatment for NDO, reduced TRPV1 expression in bladder biopts of patients (Giannantoni et al ., ). This might indicate that, in addition to its known effects on the release of ACh by efferent neurons, reduction of TRPV1‐mediated afferent signals could contribute to the beneficial effects of botulinum toxin A in NDO patients.…”
Section: Lutd With Bladder Overactivitymentioning
confidence: 97%